Investor Presentaiton
Profitability supported by scalability and efficiency gains enabling
additional innovation and commercial investments
Gross Profit development, %*
YTD 22/23 Gross Profit negatively impacted by inflationary headwind on input
costs (raw materials, energy, freight, labour)
Cost item
Development, in % of revenue*
+1.7%-points
67.7
68.0
-1.0%-pt
68.5
68.8
66.7
-68
18/19
19/20
20/21
21/22
YTD 22/23 Long-term
*Atos Medical included in FY 21/22 with eight months of impact. Long-term expectations include Atos Medical
38
29.0
28.7
28.2
30.1
30.7
28-30
Distribution
+0.4%-point
4.5
4.6
4.2
4.1
3.9
~4
Admin
-0.4%-point
3.9
3.8
3.9
3.8
~4
3.5
R&D
18/19
19/20 20/21
21/22
YTD Long-
22/23 term
FY 21/22 and YTD 22/23 cost items include impact from the Atos Medical
acquisition, of which DKK 152m and DKK 159m respectively in amortization costs
(included under distribution cost)
ColoplastView entire presentation